How I manage severe bacterial infections in people who inject drugs
- PMID: 38316359
- DOI: 10.1016/j.cmi.2024.01.022
How I manage severe bacterial infections in people who inject drugs
Abstract
Background: Injecting drug use is a risk factor for severe bacterial infection, but there is limited high-quality evidence to guide clinicians providing care to people who inject drugs. Management can be complicated by mistrust, stigma, and competing patient priorities.
Objectives: To review the management of severe infections in people who inject drugs, using an illustrative clinical scenario of complicated Staphylococcus aureus bloodstream infection.
Sources: The discussion is based on recent literature searches of relevant topics. Very few randomized clinical trials have focussed specifically on the management of severe bacterial infections among people who inject drugs. Most recommendations are, therefore, based on observational studies, extrapolation from other patient groups, and the experience and opinions of the authors.
Content: We discuss evidence and options regarding the following management issues for severe bacterial infections among people who inject drugs: initial management of sepsis; indications for surgical management; assessment and management of substance dependence; approaches to antibiotic administration following clinical stability; opportunistic health promotion; and secondary prevention of bacterial infections. Throughout, we highlight the importance of harm reduction and strategies to optimize patient engagement in care through a patient-centred approach.
Implications: We advocate for a multi-disciplinary trauma-informed approach to the management of severe bacterial infection among people who inject drugs. We emphasize the need for pragmatic trials to inform management guidelines, including those that are co-designed with the community. In particular, research is needed to establish the comparative effectiveness, safety, and cost-effectiveness of inpatient intravenous antibiotics vs. early oral antibiotic switch, outpatient parenteral therapy, and long-acting lipoglycopeptide antibiotics in this scenario.
Keywords: Addiction medicine; Bloodstream infection; Harm reduction; People who inject drugs; Staphylococcus aureus.
Copyright © 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Outcomes of Partial Oral Antibiotic Treatment for Complicated Staphylococcus aureus Bacteremia in People Who Inject Drugs.Clin Infect Dis. 2023 Feb 8;76(3):487-496. doi: 10.1093/cid/ciac714. Clin Infect Dis. 2023. PMID: 36052413 Free PMC article.
-
Review of management priorities for invasive infections in people who inject drugs: highlighting the need for patient-centred multidisciplinary care.Med J Aust. 2022 Jul 18;217(2):102-109. doi: 10.5694/mja2.51623. Epub 2022 Jun 26. Med J Aust. 2022. PMID: 35754144 Free PMC article. Review.
-
Commentary: the value of PrEP for people who inject drugs.J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21112. doi: 10.7448/IAS.19.7.21112. eCollection 2016. J Int AIDS Soc. 2016. PMID: 27760686 Free PMC article.
-
"We don't need services. We have no problems": exploring the experiences of young people who inject drugs in accessing harm reduction services.J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):19442. doi: 10.7448/IAS.18.2.19442. eCollection 2015. J Int AIDS Soc. 2015. PMID: 25724510 Free PMC article.
-
Oral antibiotic therapy in people who inject drugs (PWID) with bacteraemia.Swiss Med Wkly. 2020 Jun 21;150:w20259. doi: 10.4414/smw.2020.20259. eCollection 2020 Jun 1. Swiss Med Wkly. 2020. PMID: 32564343 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical